In a Phase 2 clinical trial for NP001, a monocyte and macrophage regulator, CRP levels were identified as a pharmacodynamic marker for ALS treatment response (Lunetta et al., 2017). The gene discussed is CRP; the disease is amyotrophic lateral sclerosis.